Claims for Patent: 9,937,269

Summary for Patent: 9,937,269

Title:	RTEF-1 variants and the use thereof for inhibition of angiogenesis
Abstract:	Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
Inventor(s):	Stout; J. Timothy (Houston, TX), McFarland; Trevor J. (Portland, OR), Appukuttan; Binoy (Adelaide, AU)
Assignee:	Research Development Foundation (Carson City, NV)
Application Number:	15/369,583
Patent Claims:	1. A method for treating a patient with an angiogenic disorder comprising administering to the patient an effective amount of a therapeutic composition comprising a nucleic acid expression vector comprising a nucleic acid sequence encoding an amino acid sequence at least 95% identical to SEQ ID NO:3, wherein the composition is administered to the site of the angiogenic disorder and at least one symptom of the angiogenic disorder is treated. 2. The method of claim 1, wherein the angiogenic disorder is ocular neovascularization, arterio-venous malformations, coronary restenosis, peripheral vessel restenosis, glomerulonephritis or rheumatoid arthritis. 3. The method of claim 2, wherein the angiogenic disorder is ocular neovascularization. 4. The method of claim 1, wherein the disorder is macular degeneration, corneal graft rejection, corneal neovascularization, retinopathy of prematurity (ROP) or diabetic retinopathy. 5. The method of claim 4, wherein the disorder is age-related macular degeneration (AMD). 6. The method of claim 1, further comprising administering a second antiangiogenic therapy. 7. The method of claim 6, wherein the second anti-angiogenic therapy is an antibody that binds to VEGF, a VEGF receptor, FGF, an FGF receptor, bevacizumab, ranibizumab, or pegaptanib sodium. 8. The method of claim 1, wherein the angiogenic disorder is a cancer. 9. The method of claim 8, wherein the cancer is a metastatic cancer. 10. The method of claim 8, wherein the cancer is a bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, eye, gastrointestinal, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus cancer. 11. The method of claim 10, wherein the cancer is ocular melanoma. 12. The method of claim 8, further comprising administering a second anticancer therapy. 13. The method of claim 12, wherein the second anticancer therapy is a chemotherapy, surgical therapy, an immunotherapy or a radiation therapy. 14. The method of claim 1, wherein the patient is a human. 15. The method of claim 1, wherein the therapeutic composition is administered to the eye. 16. The method of claim 15, wherein the therapeutic composition is administered to the eye topically or by intraocular injection. 17. The method of claim 16, wherein the therapeutic composition is administered as an eye drop. 18. The method of claim 1, wherein the nucleic acid expression vector is further defined as a viral expression vector. 19. The method of claim 18, wherein the viral expression vector is an adenovirus, adeno-associated virus, herpes virus, SV-40 virus, retrovirus or vaccinia virus vector. 20. The method of claim 19, wherein the viral expression vector is an adeno-associated virus. 21. The method of claim 19, wherein the viral expression vector is a lentiviral expression vector. 22. The method of claim 21, wherein the lentiviral expression vector is an HIV vector. 23. The method of claim 1, wherein the expression vector comprises a cell type specific or inducible promoter. 24. The method of claim 23, wherein the inducible promoter is a hypoxia inducible promoter. 25. The method of claim 23, wherein the inducible promoter is an angiogenesis inducible promoter.

Details for Patent 9,937,269

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-06-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2027-06-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2027-06-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2027-06-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2027-06-06